PFE +2.70% NVDA -2.20% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Treasury bonds offer steady, risk-free income, but Pfizer (NYSE: PFE) brings something extra to the table: a roughly 6% dividend yield and the potential for a massive turnaround. The pharmaceutical giant is expanding its portfolio beyond its COVID-19 vaccine, giving investors a shot at significant upside while they're paid to wait today.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
For years, Pfizer was known for its COVID-19 vaccine and antiviral treatments. Those products demonstrated the company's ability to develop and commercialize medicines on a global scale. But the investment case is now increasingly focused on its broader portfolio.
In its second-quarter results, Pfizer reported that revenue from launched and acquired products grew 18% year over year. Management also raised the midpoint of its full-year guidance, driven by stronger-than-expected performance from non-COVID products.
This is an encouraging development for investors who want to see Pfizer generate growth from a wider range of medicines rather than demand tied to the pandemic.
The company's product line spans several important areas of healthcare, including cancer, cardiovascular disease, and rare diseases. Treatments like Eliquis, Padcev, and Vyndaqel have supported the business, while acquired products have expanded Pfizer's commercial reach.
This breadth gives Pfizer several opportunities to grow. Its portfolio of existing medicines provides stable growth, while bringing new treatments to market helps accelerate it. But the biggest opportunity lies in another growth engine entirely: oncology.
If there's one area where Pfizer can build on its existing strengths, it's with its cancer treatments.
The company has been expanding its oncology business through acquisitions, partnerships, and research. And today, Pfizer's portfolio includes established treatments such as Padcev and Lorbrena, while its development programs explore new medicines and combinations for breast, prostate, bladder, and lung cancers.
But the opportunity isn't just about launching a new cancer drug. It's to improve existing treatments, expand their use into earlier stages of the disease, and develop new therapies for patients who need better options.
Pfizer is also investing in new approaches, including antibody-drug conjugates, which means attaching cancer-killing agents directly to targeted cells, and bispecific antibodies, which help direct the immune system against tumors. These biologics could open new avenues for treating cancers that remain difficult to manage.
The company is also making moves to strengthen its pipeline. For example, Pfizer entered into a global collaboration with Innovent Biologics covering 12 early-stage cancer medicine programs. The agreement includes antibody-drug conjugates and multispecific antibodies, giving Pfizer access to more research programs that complement its existing oncology business.
Granted, not every experimental medicine will become a commercial success. But a broader pipeline creates more opportunities for promising candidates to emerge. Still, potential alone doesn't pay the bills today. That's where Pfizer's dividend comes in.
Pfizer declared a quarterly dividend of $0.43 in June 2026. The company says the payment is its 351st consecutive quarterly dividend, translating to a forward annual dividend yield of just over 6%.
Compared to a Treasury bond at today's prices, Pfizer's share price and dividend depend on its business performance. The appeal lies in the combination of an established pharmaceutical business, a reliable dividend, and a pipeline capable of creating new sources of growth.
The dividend gives investors a reliable stream of income while the company advances its research programs, expands its oncology franchise, and develops its obesity portfolio.
Looking ahead, if new medicines succeed, the business could benefit from additional revenue and earnings, pushing its share price higher. That gives investors more than just dividend income, and it raises the question: Does this combination make Pfizer a buy today?
Owning Pfizer stock today offers a compelling alternative to owning Treasury bonds. With a dividend yield above 6%, investors are paid to wait while the company advances its next generation of cancer treatments, obesity drugs, and other promising medicines. If its pipeline delivers, investors could benefit from both steady income and capital gains.
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $379,986!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,404,152!*
Now, it's worth noting Stock Advisor's total average return is 948% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of October 14, 2026.
Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.
Forget Treasury Bonds: This 6%-Yielding Pharma Stock Pays You to Wait for Its Pipeline was originally published by The Motley Fool
